Gland Pharma Ltd

Small Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Goldman Sachs has reiterated its 'Sell' rating on Gland Pharma, setting a target price of Rs 1,525. This reflects a cautious outlook on the stock.

Goldman Sachs Maintains 'Sell' Rating on Gland Pharma - 06 Mar, 2026

Gland Pharma's CEO Shyamakant Giri announced his resignation effective April 30, 2026. The company also received tentative USFDA approval for Brimonidine Tartrate Ophthalmic Solution, indicating strong market potential.

Gland Pharma CEO Resigns; USFDA Approval Received - 04 Mar, 2026

Gland Pharma Ltd appointed Dr. Jitendra Gangwal as Vice-President (R&D) and experienced a 1.07% stock increase, marking its third consecutive gain.

Gland Pharma Appoints New VP and Sees Stock Gains - 18 Feb, 2026

Gland Pharma has received USFDA approval for Zoledronic Acid Injection, indicated for treating hypercalcemia of malignancy and multiple myeloma, with expected US sales of $6.7 million.

Gland Pharma Secures USFDA Approval for Injection - 06 Feb, 2026

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Mutual Funds have increased holdings from 30.19% to 31.42% in Dec 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

Revenue is up for the last 5 quarters, 1.44K Cr → 1.75K Cr (in ₹), with an average increase of 4.8% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

Netprofit is up for the last 2 quarters, 183.68 Cr → 261.48 Cr (in ₹), with an average increase of 29.8% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

Promoters holdings remained unchanged at 51.83% of holdings in Dec 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

In the last 3 years, Torrent Pharmaceuticals Ltd has given 193.5% return, outperforming this stock by 147.2%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Against Peers

In the last 1 year, Torrent Pharmaceuticals Ltd has given 44.8% return, outperforming this stock by 39.9%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

In the last 3 months, GLAND stock has moved down by -0.2%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Dip

Retail Investor have decreased holdings from 7.63% to 7.61% in Dec 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Foreign Institutions have decreased holdings from 7.91% to 7.58% in Dec 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

S&P BSE 150 MidCap

Nifty Smallcap 50

Nifty Smallcap 250

S&P BSE 250 LargeMidCap

NIFTY PHARMA

Nifty MidSmallcap 400

Nifty MNC

BSE Healthcare

Nifty 500

Nifty Small 100

S&P BSE 400 MidSmallCap

BSE 500

HDFC Mid Cap Fund -Direct Plan - Growth Option

SBI Large & Midcap Fund Direct Growth

Mirae Asset Large & Midcap Fund Direct Plan Growth

ICICI Prudential India Opportunities Fund Direct Growth

Nippon India Growth Mid Cap Fund - Direct Plan - Growth Mid Cap

Gland Pharma Ltd’s net profit jumped 27.74% since last year same period to ₹261.48Cr in the Q3 2025-2026. On a quarterly growth basis, Gland Pharma Ltd has generated 42.36% jump in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	-0.18	Bullish
CCI (20)	477.73	Bearish
RSI (14)	57.16	Neutral
Momentum (10)	3.3	Bearish
ADI (14)	21.22	Neutral
Ultimate Oscillator (7,14,28)	24.53	Bearish

Name	Value	Action
SMA (20)	1674.89	Bullish
EMA (20)	1675.35	Bullish
VWMA (20)	1674.92	Bullish
SMA (50)	1676.42	Bullish
EMA (50)	1676.43	Bullish
SMA (200)	1688.23	Bearish
EMA (200)	1683.12	Bearish
KAMA (200)	1676.84	Bullish
DEMA (200)	1678.53	Bearish

Gland Pharma Ltd (GLAND)

Summary

Overall

Oscillators

Moving Averages